You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Polynitroxylated Pegylated Hemoglobin for Traumatic Brian Injury Resuscitation

    SBC: SYNZYME TECHNOLOGIES LLC            Topic: 102

    DESCRIPTION provided by applicant Traumatic brain injury TBI is a leading cause of morbidity and mortality especially when complicated by secondary insults such as hypotension Vulnerability of TBI patients to hypotension is well recognized and identifies a key need for new approaches The goal of this proposal is to develop to IND a neuroprotective hyper colloid oxygen therapeutic polynit ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. A high resolution and high DQE detector optimized for mammography using single shot bi directional tri contrast imaging

    SBC: SIGRAY, INC.            Topic: NIBIB

    DESCRIPTION provided by applicant X ray tricontrast imaging provides three different modes of contrast absorption contrast the mechanism behind how conventional medical X ray imaging equipment images phase contrast which provides up to X more contrast than absorption based contrast for soft tissue and scatter contrast which provides information of features at dimensions smaller than ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Enhancing Confidentiality of Research Files Based on Medicare Data

    SBC: ACUMEN LLC            Topic: NIA

    DESCRIPTION provided by applicant In the andquot Enhancing Confidentiality of Research Files Based on Medicare Dataandquot project Acumen LLC aims to expand the overall capabilities of researchers to use survey linked Medicare claims data Currently the process for obtaining approval from the Centers for Medicare andamp Medicaid Services CMS to access these files entails significant paper ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Developing small molecule inhibitors of TLR for treatment of rheumatoid arthritis

    SBC: DYNAVAX TECHNOLOGIES CORPORATION            Topic: NIAID

    DESCRIPTION provided by applicant Autoimmune diseases like rheumatoid arthritis RA develop when the immune response targets self antigens leading to inflammation and tissue destruction There is now considerable evidence that recognition of self nucleic acids through toll like receptors TLRs can contribute significantly to sterile inflammation and autoimmunity with the clearest example b ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Innovating Tablet Based Cognitive Assessment for CNS Disorders of Aging

    SBC: NEUROCOG TRIALS            Topic: NIA

    DESCRIPTION provided by applicant Aging populations have become a key target for therapeutics developers particularly for indications impacting cognitive function Conditions such as Alzheimerandapos s disease and vascular dementia affect the quality of life of aging Americans largely due to their impact on cognitive function with insufficient therapeutic options Recent reports indicate tha ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. CTL for supertype natural IgE cytotoxic peptide (nECP) to guard against allergic asthma

    SBC: IGE THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTIONprovided by applicantAllergic asthma is a multi faceted inflammatory disease in the lungIgE and Thmediated inflammation play a critical role in extrinsic allergic asthmaOur labs have identified naturally processed IgE cytotoxic peptidesnECPon IgE producing cellswhich serve as CTL vaccineThe feasibility of using nECP with helper peptide PADRE as a universal IgE vaccineor vaccineto treat ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Therapeutic antibody for RSV

    SBC: TRELLIS BIOSCIENCE, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Respiratory syncytial virus RSV is a leading cause of lower respiratory tract disease leading annually to deaths and million hospitalizations of young children worldwide Immune prophylaxis with a monoclonal antibody mAb Synagis tm Medimmune Inc was shown to be effective years ago to reduce complications of infection in premature birth ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Low Cost Instrument free Point of care Platform for Multiplexed Chlamydia Diagnostics

    SBC: Lucira Health, Inc.            Topic: NIAID

    Abstract Chlamydia trachomatis Ct is the most common cause of bacterial sexually transmitted diseases STD with million annual cases worldwide and million U S cases in Most female and male infections are asymptomatic facilitating unchecked transmission that can result in pelvic inflammatory disease infertility chronic pelvic pain and life threatening ectopic pregnancy Ct ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Synthesis of bone selective osteogenic oxysterols

    SBC: Max Biopharma, Inc.            Topic: NIAMS

    DESCRIPTION provided by applicant Osteoporosis affects million Americans and another million are osteopenic and at risk for developing osteoporosis Since the s bisphosphonate drug therapy has produced clinical benefits such as improved bone density and reduced fracture risk by slowing osteoclastic bone resorption Many of the existing anti resorptive drugs are plagued with untowar ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Recombinant Hyperimmune Gammaglobulin for Primary Immunodeficiency

    SBC: Gigagen, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant The Specific Aim of this SBIR direct to Phase II project is to develop natural repertoire recombinant intravenous immunoglobulin rIVIg andquot hyperimmunesandquot against common pathogens for patients with primary immune deficiency PID PID is a diverse family of congenital disorders including common variable immune deficiency CVID and X linked agammaglobulinemia X ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government